First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
New England Journal of Medicine · 30.04.2026 · 394 (17) · 1675-1684
DOI: 10.1056/nejmoa2516969 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 30.04.2026. Verfasst von John V Heymach und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Erb-b2 Receptor Tyrosine Kinases, Lung Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo.
- Institut Curie, Institut du Thorax Curie-Montsouris, Paris.
- Paris-Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Versailles, France.
- Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam.
- Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam.
Förderung
- Boehringer Ingelheim
Zitieren
APA
Heymach, J. V., Yamamoto, N., Girard, N., Ruiter, G., Smit, E. F., Planchard, D., Nadal, E., Wu, Y. L., Zugazagoitia, J., Tu, H. Y., Baik, C. S., Yoh, K., Soo, R. A., Zhao, Y., Sabari, J. K., Wermke, M., Scheffler, M., Ahn, M. J., Fernamberg, K., …, & Beamion LUNG-1 Investigators (2026). First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 394(17), 1675-1684. https://doi.org/10.1056/nejmoa2516969
Vancouver
Heymach JV, Yamamoto N, Girard N, Ruiter G, Smit EF, Planchard D, et al. First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2026;394(17):1675-1684. doi:10.1056/nejmoa2516969
BibTeX
@article{Heymach2026,
author = {Heymach, John V and Yamamoto, Noboru and Girard, Nicolas and Ruiter, Gerrina and Smit, Egbert F and Planchard, David and Nadal, Ernest and Wu, Yi-Long and Zugazagoitia, Jon and Tu, Hai-Yan and Baik, Christina S and Yoh, Kiyotaka and Soo, Ross A and Zhao, Yanqiu and Sabari, Joshua K and Wermke, Martin and Scheffler, Matthias and Ahn, Myung-Ju and Fernamberg, Kristie and Schroeter, Lukas and Sadrolhefazi, Behbood and Thamer, Claus and Eigenbrod-Giese, Sabina and Popat, Sanjay and Beamion LUNG-1 Investigators, Beamion LUNG-1 Investigators},
title = {First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {17},
pages = {1675--1684},
doi = {10.1056/nejmoa2516969}
}
EUVIMED